Last reviewed · How we verify
recombinant adjuvanted zoster vaccine
This vaccine stimulates the immune system to recognize and respond to varicella-zoster virus (VZV) antigens, with an adjuvant component enhancing the immune response.
This vaccine stimulates the immune system to recognize and respond to varicella-zoster virus (VZV) antigens, with an adjuvant component enhancing the immune response. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia (PHN).
At a glance
| Generic name | recombinant adjuvanted zoster vaccine |
|---|---|
| Sponsor | Wuerzburg University Hospital |
| Drug class | Recombinant subunit vaccine with adjuvant |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant VZV glycoprotein E (gE) antigen combined with an adjuvant system (AS01B) that activates innate and adaptive immunity. The adjuvant enhances T-cell and B-cell responses to the antigen, providing stronger and more durable protection against herpes zoster (shingles) compared to non-adjuvanted vaccines.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of post-herpetic neuralgia (PHN)
Common side effects
- Injection site erythema
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older (PHASE2)
- Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older (PHASE1)
- Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (NA)
- A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years (PHASE1)
- Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: